Search

Your search keyword '"Chadburn A"' showing total 2,506 results
Start Over Author "Chadburn A"
2,506 results on '"Chadburn A"'

101. 3156 – CLASSIC HODGKIN LYMPHOMAS DISPLAY NEURONAL-GLIAL LINEAGE REPROGRAMMING

Author

Saurty-Seerunghen, Mirca, Moein, Sara, Pak, Minwoo, Abera, Tsega-Ab, Sun, Xiaotian, Sharma, Sohani, Lama, Chhiring, Sakaguchi, Olivia, Totwani, Mansi, Rosenberg, Shira, Gao, Qi, Parghi, Neelang, Kong, Isabella, Chadburn, Amy, Nie, Kui, Alonso, Vicenta Trujillo, Xiang, Jenny, Cesarman, Ethel, Tam, Wayne, Roshal, Mikhail, Roth, Lisa Giulino, and Nam, Anna

Published
2024
Full Text
View/download PDF

102. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease

Author

van Rhee, Frits, Voorhees, Peter, Dispenzieri, Angela, Fosså, Alexander, Srkalovic, Gordan, Ide, Makoto, Munshi, Nikhil, Schey, Stephen, Streetly, Matthew, Pierson, Sheila K., Partridge, Helen L., Mukherjee, Sudipto, Shilling, Dustin, Stone, Katie, Greenway, Amy, Ruth, Jason, Lechowicz, Mary Jo, Chandrakasan, Shanmuganathan, Jayanthan, Raj, Jaffe, Elaine S., Leitch, Heather, Pemmaraju, Naveen, Chadburn, Amy, Lim, Megan S., Elenitoba-Johnson, Kojo S., Krymskaya, Vera, Goodman, Aaron, Hoffmann, Christian, Zinzani, Pier Luigi, Ferrero, Simone, Terriou, Louis, Sato, Yasuharu, Simpson, David, Wong, Raymond, Rossi, Jean-Francois, Nasta, Sunita, Yoshizaki, Kazuyuki, Kurzrock, Razelle, Uldrick, Thomas S., Casper, Corey, Oksenhendler, Eric, and Fajgenbaum, David C.

Published
2018
Full Text
View/download PDF

104. Machine Learning Highlights Downtrending of COVID-19 Patients with a Distinct Laboratory Profile

Author

He S. Yang, Yu Hou, Hao Zhang, Amy Chadburn, Lars F. Westblade, Richard Fedeli, Peter A. D. Steel, Sabrina E. Racine-Brzostek, Priya Velu, Jorge L. Sepulveda, Michael J. Satlin, Melissa M. Cushing, Rainu Kaushal, Zhen Zhao, and Fei Wang

Subjects
Computer applications to medicine. Medical informatics, R858-859.7
Abstract

Background. New York City (NYC) experienced an initial surge and gradual decline in the number of SARS-CoV-2-confirmed cases in 2020. A change in the pattern of laboratory test results in COVID-19 patients over this time has not been reported or correlated with patient outcome. Methods. We performed a retrospective study of routine laboratory and SARS-CoV-2 RT-PCR test results from 5,785 patients evaluated in a NYC hospital emergency department from March to June employing machine learning analysis. Results. A COVID-19 high-risk laboratory test result profile (COVID19-HRP), consisting of 21 routine blood tests, was identified to characterize the SARS-CoV-2 patients. Approximately half of the SARS-CoV-2 positive patients had the distinct COVID19-HRP that separated them from SARS-CoV-2 negative patients. SARS-CoV-2 patients with the COVID19-HRP had higher SARS-CoV-2 viral loads, determined by cycle threshold values from the RT-PCR, and poorer clinical outcome compared to other positive patients without the COVID12-HRP. Furthermore, the percentage of SARS-CoV-2 patients with the COVID19-HRP has significantly decreased from March/April to May/June. Notably, viral load in the SARS-CoV-2 patients declined, and their laboratory profile became less distinguishable from SARS-CoV-2 negative patients in the later phase. Conclusions. Our longitudinal analysis illustrates the temporal change of laboratory test result profile in SARS-CoV-2 patients and the COVID-19 evolvement in a US epicenter. This analysis could become an important tool in COVID-19 population disease severity tracking and prediction. In addition, this analysis may play an important role in prioritizing high-risk patients, assisting in patient triaging and optimizing the usage of resources.

Published
2021
Full Text
View/download PDF

107. A comparison of the pore-forming subunits of the ATP-sensitive potassium channel

Author

Chadburn, Andrew James and Lodwick, Dave

Subjects
572
Abstract

Kir6.1 and Kir6.2 display several key differences in characteristics e.g. Kir6.2 can open spontaneously upon removal of inhibitory nucleotides while Kir6.1 cannot. Residues responsible for some of these disparate properties have been mapped to the N-terminus of Kir6.0. Mutant cDNAs for these subunits were created where amino acid(s) were taken from one isoform and replaced with the corresponding residue(s) from the other. The whole cell and inside-out patch clamp techniques were used to assess the current density, spontaneous opening, ATP sensitivity and unitary conductance of these mutant channels. All mutants showed similar current density to their parent channels, suggesting similar expression. One mutant, which exchanged residues 15-17 of Kir6.2 (TRL) for ARI, had significantly lower conductance than wild type, possibly due to allosteric modulation of the conduction pathway. Simultaneous mutation of a group of residues from Kir6.2 (S37A, K39S, N41A and V44L) reduced relative activation, a measure of spontaneous opening. However, mutation of these residues individually had no effect, suggesting that they interact to affect spontaneous opening in wild type channels. 14-3-3 are a family of chaperone and scaffold proteins shown to interact with several ion channels both functionally and during expression. 14-3-3 ε and ζ have been implicated in expression of KATP channels. To try and address the poor expression of Kir6.1-based channels, 14-3-3 ε and ζ were co-expressed with KATP channels. No effect was seen with any 14-3-3 isoforms co-expressed with Kir6.1. However, 14-3-3 ε significantly increased current density of Kir6.2/SUR2A channels. Co-expression of 14-3-3 ε and ζ attenuated this effect. The disparate effects of different combinations of these 14-3-3 isoforms suggest that their dimerisation may play a role in the effect seen here.

Published
2010

109. Response-adapted therapy with infusional EPOCH chemotherapy plus rituximab in HIV-associated, B-cell non-Hodgkin's lymphoma

Author

Joseph A. Sparano, Jeannette Y. Lee, Lawrence D. Kaplan, Juan Carlos Ramos, Richard F. Ambinder, William Wachsman, David Aboulafia, Ariela Noy, David H. Henry, Lee Ratner, Ethel Cesarman, Amy Chadburn, and Ronald Mitsuyasu

Subjects
Diseases of the blood and blood-forming organs, RC633-647.5
Abstract

Four cycles of rituximab plus CHOP chemotherapy is as effective as 6 cycles in low-risk diffuse large B-cell lymphoma (DLBCL). Here we report a post-hoc analysis of a prospective clinical trial in patients with HIV-associated DLBCL and high-grade lymphoma treated with 4–6 cycles of EPOCH plus rituximab based a response-adapted treatment strategy. 106 evaluable patients with HIV-associated DLBCL or high-grade CD20-positive non-Hodgkin's lymphoma were randomized to receive rituximab (375 mg/m2) given either concurrently prior to each infusional EPOCH cycle, or sequentially (weekly for 6 weeks) following completion of EPOCH. EPOCH consisted of a 96-hour IV infusion of etoposide, doxorubicin, and vincristine plus oral prednisone followed by IV bolus cyclophosphamide every 21 days for 4 to 6 cycles. Patients received 2 additional cycles of therapy after documentation of a complete response (CR) by computerized tomography after cycles 2 and 4. 64 of 106 evaluable patients (60%, 95% CI 50%, 70%) had a CR in both treatment arms. The 2-year event-free survival (EFS) rates were similar in the 24 patients with CR who received 4 or fewer EPOCH cycles (78%, 95% confidence intervals [55%, 90%]) due to achieving a CR after 2 cycles, compared with those who received 5-6 cycles of EPOCH (85%, 95% CI 70%, 93%) because a CR was first documented after cycle 4. A response-adapted strategy may permit a shorter treatment duration without compromising therapeutic efficacy in patients with HIV-associated lymphoma treated with EPOCH plus rituximab, which merits further evaluation in additional prospective trials. Clinical Trials.gov identifier NCT00049036

Published
2020
Full Text
View/download PDF

111. Land-use emissions play a critical role in land-based mitigation for Paris climate targets

Author

Anna B. Harper, Tom Powell, Peter M. Cox, Joanna House, Chris Huntingford, Timothy M. Lenton, Stephen Sitch, Eleanor Burke, Sarah E. Chadburn, William J. Collins, Edward Comyn-Platt, Vassilis Daioglou, Jonathan C. Doelman, Garry Hayman, Eddy Robertson, Detlef van Vuuren, Andy Wiltshire, Christopher P. Webber, Ana Bastos, Lena Boysen, Philippe Ciais, Narayanappa Devaraju, Atul K. Jain, Andreas Krause, Ben Poulter, and Shijie Shu

Subjects
Science
Abstract

Land-based mitigation for meeting the Paris climate target must consider the carbon cycle impacts of land-use change. Here the authors show that when bioenergy crops replace high carbon content ecosystems, forest-based mitigation could be more effective for CO2 removal than bioenergy crops with carbon capture and storage.

Published
2018
Full Text
View/download PDF

112. Representation of dissolved organic carbon in the JULES land surface model (vn4.4_JULES-DOCM)

Author

M. Nakhavali, P. Friedlingstein, R. Lauerwald, J. Tang, S. Chadburn, M. Camino-Serrano, B. Guenet, A. Harper, D. Walmsley, M. Peichl, and B. Gielen

Subjects
Geology, QE1-996.5
Abstract

Current global models of the carbon (C) cycle consider only vertical gas exchanges between terrestrial or oceanic reservoirs and the atmosphere, thus not considering the lateral transport of carbon from the continents to the oceans. Therefore, those models implicitly consider all of the C which is not respired to the atmosphere to be stored on land and hence overestimate the land C sink capability. A model that represents the whole continuum from atmosphere to land and into the ocean would provide a better understanding of the Earth's C cycle and hence more reliable historical or future projections. A first and critical step in that direction is to include processes representing the production and export of dissolved organic carbon in soils. Here we present an original representation of dissolved organic C (DOC) processes in the Joint UK Land Environment Simulator (JULES-DOCM) that integrates a representation of DOC production in terrestrial ecosystems based on the incomplete decomposition of organic matter, DOC decomposition within the soil column, and DOC export to the river network via leaching. The model performance is evaluated in five specific sites for which observations of soil DOC concentration are available. Results show that the model is able to reproduce the DOC concentration and controlling processes, including leaching to the riverine system, which is fundamental for integrating terrestrial and aquatic ecosystems. Future work should include the fate of exported DOC in the river system as well as DIC and POC export from soil.

Published
2018
Full Text
View/download PDF

113. Aspects of the Iron Age coinage of northern East Anglia with especial reference to hoards

Author

Chadburn, Amanda Dorothy Barras

Subjects
737.49362, CJ Numismatics
Abstract

This thesis considers the Iron Age coinages found in hoards within a particular study area in northern East Anglia. The study area was widely defined to attempt to capture all the coins considered by previous scholars to belong to the Iron Age tribe, the Iceni. Other coins of the Iceni outside the study area found in hoards are also considered. The historical context and previous numismatic research on these coins is reviewed. All coin hoards within the study area are fully described and reviewed, and two hoards are presented as detailed case studies, including a die study on the largest number of Iron Age hoard coins yet undertaken. A classification of the coin series is given, with each coin type fully described, illustrated, and photographed. The distribution of the coin hoards within and outside the study area is considered, results discussed and conclusions drawn. A chronology is suggested for the coin types and for the deposition of the hoards. The manufacture and minting of the coins is discussed and suggestions for mint sites given. Finally, a number of detailed conclusions are drawn.

Published
2006

114. Brentuximab vedotin with AVD for stage II–IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial

Author

Rubinstein, Paul G, primary, Moore, Page C, additional, Bimali, Milan, additional, Lee, Jeanette Y, additional, Rudek, Michelle A, additional, Chadburn, Amy, additional, Ratner, Lee, additional, Henry, David H, additional, Cesarman, Ethel, additional, DeMarco, Camille E, additional, Costagliola, Dominique, additional, Taoufik, Yassine, additional, Ramos, Juan Carlos, additional, Sharon, Elad, additional, Reid, Erin G, additional, Ambinder, Richard F, additional, Mitsuyasu, Ronald, additional, Mounier, Nicolas, additional, Besson, Caroline, additional, Noy, Ariela, additional, Barta, Stefan K., additional, Hamdan, Ayad, additional, Boué, François, additional, Delobel, Pierre, additional, Galicier, Lionel, additional, Coppo, Paul, additional, and Ghesquières, Hervé, additional

Published
2023
Full Text
View/download PDF

115. Locus specific human endogenous retroviruses reveal new lymphoma subtypes

Author

Singh, Bhavya, primary, Dopkins, Nicholas, additional, Fei, Tongyi, additional, Marston, Jez L., additional, Michael, Stephanie, additional, Reyes-Gopar, Helena, additional, Curty, Gislaine, additional, Heymann, Jonas J., additional, Chadburn, Amy, additional, Martin, Peter, additional, Leal, Fabio E., additional, Cesarman, Ethel, additional, Nixon, Douglas F., additional, and Bendall, Matthew L., additional

Published
2023
Full Text
View/download PDF

116. Pathology

Author

Cesarman, Ethel, Chadburn, Amy, Hentrich, Marcus, editor, and Barta, Stefan K., editor

Published
2016
Full Text
View/download PDF

117. International, evidence-based consensus diagnostic criteria for HHV-8–negative/idiopathic multicentric Castleman disease

Author

Fajgenbaum, David C., Uldrick, Thomas S., Bagg, Adam, Frank, Dale, Wu, David, Srkalovic, Gordan, Simpson, David, Liu, Amy Y., Menke, David, Chandrakasan, Shanmuganathan, Lechowicz, Mary Jo, Wong, Raymond S.M., Pierson, Sheila, Paessler, Michele, Rossi, Jean-François, Ide, Makoto, Ruth, Jason, Croglio, Michael, Suarez, Alexander, Krymskaya, Vera, Chadburn, Amy, Colleoni, Gisele, Nasta, Sunita, Jayanthan, Raj, Nabel, Christopher S., Casper, Corey, Dispenzieri, Angela, Fosså, Alexander, Kelleher, Dermot, Kurzrock, Razelle, Voorhees, Peter, Dogan, Ahmet, Yoshizaki, Kazuyuki, van Rhee, Frits, Oksenhendler, Eric, Jaffe, Elaine S., Elenitoba-Johnson, Kojo S.J., and Lim, Megan S.

Published
2017
Full Text
View/download PDF

118. Development of an electronic patient-reported outcome measure (ePROM) system to aid the management of patients with advanced chronic kidney disease

Author

Kyte, Derek, Anderson, Nicola, Auti, Ram, Aiyegbusi, Olalekan Lee, Bishop, Jon, Bissell, Andrew, Brettell, Elizabeth, Calvert, Melanie, Chadburn, Marie, Cockwell, Paul, Dutton, Mary, Eddington, Helen, Forster, Elliot, Hadley, Gabby, Ives, Natalie J., Jackson, Louise, O’Brien, Sonja, Price, Gary, Sharpe, Keeley, Stringer, Stephanie, Stephenson, Gael, Verdi, Rav, Waters, Judi, Wilcockson, Adrian, and Williams, Jim

Published
2020
Full Text
View/download PDF

119. Mutations of ATM Confer a Risk of Inferior Survival in Patients with TP53-wild Type Mantle Cell Lymphoma

Author

Jean L. Koff, Rachel Kositsky, David L Jaye, Michael C. Churnetski, Katelin Baird, Colin B. O'Leary, Christopher R. Flowers, Sirpa Leppa, Marja-Liisa Karjalainen-Lindsberg, Shaoying Li, Jie Xu, Mette Ø Pedersen, Anne Ortved Gang, Kikkeri N Naresh, Rebecca J Leeman-Neill, Kwok Him Rex Au Yeung, Hina Naushad Qureishi, Javeed Iqbal, Jennifer R Chapman-Fredricks, Chad M. McCall, Michael Crump, Amy Chadburn, Erin C. Mulvey, Izidore S. Lossos, Sandra L. Ondrejka, Eric D. Hsi, Abner Louissaint, Haley Martin, Eric Tse, Cassandra Love, Tushar Dave, Clay Parker, Choon Kiat Ong, Andrew G Evans, Amir Behdad, Lixin Yang, Nishitha Reddy, Mary Ann Arildsen, Ridas Juskevicius, Jiong Yan, Magdalena Czader, Andrew M. Evens, Dina Sameh Soliman, Yuri Fedoriw, Sandeep S. Dave, and Jonathon B. Cohen

Subjects
Immunology, Cell Biology, Hematology, Biochemistry
Published
2022

120. Protocol for a multicentre randomised controlled trial of STeroid Administration Routes For Idiopathic Sudden sensorineural Hearing loss: The STARFISH trial.

Author

Smith, Matthew E., Knappett, Rachel, Vickers, Deborah, White, David, Schramm, Chris J., Mehta, Samir, Sun, Yongzhong, Watkins, Ben, Chadburn, Marie, Jarrett, Hugh, James, Karen, Brettell, Elizabeth, Roberts, Tracy E., Bance, Manohar L., and Tysome, James R.

Subjects
SENSORINEURAL hearing loss, EAR, INNER ear, RANDOMIZED controlled trials, AUDIOGRAM, AUDIOMETRY, STARFISHES, VERBAL behavior testing
Abstract

Idiopathic sudden sensorineural hearing loss (ISSNHL) is the rapid onset of reduced hearing due to loss of function of the inner ear or hearing nerve of unknown aetiology. Evidence supports improved hearing recovery with early steroid treatment, via oral, intravenous, intratympanic or a combination of routes. The STARFISH trial aims to identify the most clinically and cost-effective route of administration of steroids as first-line treatment for ISSNHL. STARFISH is a pragmatic, multicentre, assessor-blinded, three-arm intervention, superiority randomised controlled trial (1:1:1) with an internal pilot (ISRCTN10535105, IRAS 1004878). 525 participants with ISSNHL will be recruited from approximately 75 UK Ear, Nose and Throat units. STARFISH will recruit adults with sensorineural hearing loss averaging 30dBHL or greater across three contiguous frequencies (confirmed via pure tone audiogram), with onset over a ≤3-day period, within four weeks of randomisation. Participants will be randomised to 1) oral prednisolone 1mg/Kg/day up to 60mg/day for 7 days; 2) intratympanic dexamethasone: three intratympanic injections 3.3mg/ml or 3.8mg/ml spaced 7±2 days apart; or 3) combined oral and intratympanic steroids. The primary outcome will be absolute improvement in pure tone audiogram average at 12-weeks following randomisation (0.5, 1.0, 2.0 and 4.0kHz). Secondary outcomes at 6 and 12 weeks will include: Speech, Spatial and Qualities of hearing scale, high frequency pure tone average thresholds (4.0, 6.0 and 8.0kHz), Arthur Boothroyd speech test, Vestibular Rehabilitation Benefit Questionnaire, Tinnitus Functional Index, adverse events and optional weekly online speech and pure tone hearing tests. A health economic assessment will be performed, and presented in terms of incremental cost effectiveness ratios, and cost per quality-adjusted life-year. Primary analyses will be by intention-to-treat. Oral prednisolone will be the reference. For the primary outcome, the difference between group means and 97.5% confidence intervals at each time-point will be estimated via a repeated measures mixed-effects linear regression model. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

121. Air temperature and precipitation constraining the modelled wetland methane emissions in a boreal region in Northern Europe.

Author

Aalto, Tuula, Tsuruta, Aki, Mäkelä, Jarmo, Mueller, Jurek, Tenkanen, Maria, Burke, Eleanor, Chadburn, Sarah, Gao, Yao, Mannisenaho, Vilma, Kleinen, Thomas, Lee, Hanna, Leppänen, Antti, Markkanen, Tiina, Materia, Stefano, Miller, Paul, Peano, Daniele, Peltola, Olli, Poulter, Benjamin, Raivonen, Maarit, and Saunois, Marielle

Subjects
ATMOSPHERIC temperature, EDDY flux, WETLANDS, METHANE, ATMOSPHERIC models, HIGH temperatures
Abstract

Wetland methane responses to temperature and precipitation were studied in a boreal wetland-rich region in Northern Europe using ecosystem process models. Six ecosystem models (JSBACH-HIMMELI, LPX-Bern, LPJ-GUESS, JULES, CLM4.5 and CLM5) were compared to multi-model mean of ecosystem models and atmospheric inversions from the Global Carbon Project and up-scaled eddy covariance flux results for their temperature and precipitation responses and seasonal cycles of the regional fluxes. Two models with contrasting response patterns, LPX-Bern and JSBACH-HIMMELI, were used as priors in atmospheric inversions with Carbon Tracker Europe – CH4 in order to find out how the inversion attempts to change the prior fluxes in the posterior and how this alters the interpretation of the flux responses to temperature and precipitation. The inversion attempted to move emissions of both models in posterior towards co-limitation by temperature and precipitation. In general high temperature and/or high precipitation periods often resulted in high posterior emissions. This was not the case for the warm and dry period of summer 2018. The process models showed strong temperature as well as strong precipitation responses for the region (51–91 % of the variance explained by both), and the month of maximum emissions varied from May to September. However, multi-model means, inversions and up-scaled eddy covariance flux observations agreed on the month of maximum emissions, and had rather balanced temperature and precipitation responses. The set-up of different emission components (peatland emissions, mineral land fluxes) had a significant role in building up the response patterns. Considering the significant differences among the models, it is essential to pay more attention to the magnitude, composition, annual cycle and climate driver responses of wetland emissions in different regions. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

123. Applying Cost Benefit Analysis at a Community Level: A review of its use for community based climate and disaster risk management

Author

Chadburn, Oenone, Anderson, Chris, Cabot Venton, Courtenay, and Selby, Sarah

Subjects
Aid, Climate change, Economics, Conflict and disasters, Food and livelihoods, Governance and citizenship
Abstract

This report reviews 23 studies that have applied cost benefit analysis (CBA) to assess community-based disaster risk reduction and climate change adaptation projects. The review shows that CBA at a community level is adding value to our understanding of the effectiveness of efforts to reduce climate and disaster risk. The report concludes with key messages emerging from the study and outlines recommendations for addressing gaps and moving the agenda forward.

Published
2013

124. Supplementary Figure from SETD2 Haploinsufficiency Enhances Germinal Center–Associated AICDA Somatic Hypermutation to Drive B-cell Lymphomagenesis

Author

Leung, Wilfred, primary, Teater, Matt, primary, Durmaz, Ceyda, primary, Meydan, Cem, primary, Chivu, Alexandra G., primary, Chadburn, Amy, primary, Rice, Edward J., primary, Muley, Ashlesha, primary, Camarillo, Jeannie M., primary, Arivalagan, Jaison, primary, Li, Ziyi, primary, Flowers, Christopher R., primary, Kelleher, Neil L., primary, Danko, Charles G., primary, Imielinski, Marcin, primary, Dave, Sandeep S., primary, Armstrong, Scott A., primary, Mason, Christopher E., primary, and Melnick, Ari M., primary

Published
2023
Full Text
View/download PDF

125. Data from SETD2 Haploinsufficiency Enhances Germinal Center–Associated AICDA Somatic Hypermutation to Drive B-cell Lymphomagenesis

Author

Leung, Wilfred, primary, Teater, Matt, primary, Durmaz, Ceyda, primary, Meydan, Cem, primary, Chivu, Alexandra G., primary, Chadburn, Amy, primary, Rice, Edward J., primary, Muley, Ashlesha, primary, Camarillo, Jeannie M., primary, Arivalagan, Jaison, primary, Li, Ziyi, primary, Flowers, Christopher R., primary, Kelleher, Neil L., primary, Danko, Charles G., primary, Imielinski, Marcin, primary, Dave, Sandeep S., primary, Armstrong, Scott A., primary, Mason, Christopher E., primary, and Melnick, Ari M., primary

Published
2023
Full Text
View/download PDF

126. Data from The Genetic Basis of Hepatosplenic T-cell Lymphoma

Author

McKinney, Matthew, primary, Moffitt, Andrea B., primary, Gaulard, Philippe, primary, Travert, Marion, primary, De Leval, Laurence, primary, Nicolae, Alina, primary, Raffeld, Mark, primary, Jaffe, Elaine S., primary, Pittaluga, Stefania, primary, Xi, Liqiang, primary, Heavican, Tayla, primary, Iqbal, Javeed, primary, Belhadj, Karim, primary, Delfau-Larue, Marie Helene, primary, Fataccioli, Virginie, primary, Czader, Magdalena B., primary, Lossos, Izidore S., primary, Chapman-Fredricks, Jennifer R., primary, Richards, Kristy L., primary, Fedoriw, Yuri, primary, Ondrejka, Sarah L., primary, Hsi, Eric D., primary, Low, Lawrence, primary, Weisenburger, Dennis, primary, Chan, Wing C., primary, Mehta-Shah, Neha, primary, Horwitz, Steven, primary, Bernal-Mizrachi, Leon, primary, Flowers, Christopher R., primary, Beaven, Anne W., primary, Parihar, Mayur, primary, Baseggio, Lucile, primary, Parrens, Marie, primary, Moreau, Anne, primary, Sujobert, Pierre, primary, Pilichowska, Monika, primary, Evens, Andrew M., primary, Chadburn, Amy, primary, Au-Yeung, Rex K.H., primary, Srivastava, Gopesh, primary, Choi, William W. L., primary, Goodlad, John R., primary, Aurer, Igor, primary, Basic-Kinda, Sandra, primary, Gascoyne, Randy D., primary, Davis, Nicholas S., primary, Li, Guojie, primary, Zhang, Jenny, primary, Rajagopalan, Deepthi, primary, Reddy, Anupama, primary, Love, Cassandra, primary, Levy, Shawn, primary, Zhuang, Yuan, primary, Datta, Jyotishka, primary, Dunson, David B., primary, and Davé, Sandeep S., primary

Published
2023
Full Text
View/download PDF

127. Data from Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma

Author

Giulino-Roth, Lisa, primary, van Besien, Herman J., primary, Dalton, Tanner, primary, Totonchy, Jennifer E., primary, Rodina, Anna, primary, Taldone, Tony, primary, Bolaender, Alexander, primary, Erdjument-Bromage, Hediye, primary, Sadek, Jouliana, primary, Chadburn, Amy, primary, Barth, Matthew J., primary, Dela Cruz, Filemon S., primary, Rainey, Allison, primary, Kung, Andrew L., primary, Chiosis, Gabriela, primary, and Cesarman, Ethel, primary

Published
2023
Full Text
View/download PDF

128. Supplementary Tables S1 - S10 from The Genetic Basis of Hepatosplenic T-cell Lymphoma

Author

McKinney, Matthew, primary, Moffitt, Andrea B., primary, Gaulard, Philippe, primary, Travert, Marion, primary, De Leval, Laurence, primary, Nicolae, Alina, primary, Raffeld, Mark, primary, Jaffe, Elaine S., primary, Pittaluga, Stefania, primary, Xi, Liqiang, primary, Heavican, Tayla, primary, Iqbal, Javeed, primary, Belhadj, Karim, primary, Delfau-Larue, Marie Helene, primary, Fataccioli, Virginie, primary, Czader, Magdalena B., primary, Lossos, Izidore S., primary, Chapman-Fredricks, Jennifer R., primary, Richards, Kristy L., primary, Fedoriw, Yuri, primary, Ondrejka, Sarah L., primary, Hsi, Eric D., primary, Low, Lawrence, primary, Weisenburger, Dennis, primary, Chan, Wing C., primary, Mehta-Shah, Neha, primary, Horwitz, Steven, primary, Bernal-Mizrachi, Leon, primary, Flowers, Christopher R., primary, Beaven, Anne W., primary, Parihar, Mayur, primary, Baseggio, Lucile, primary, Parrens, Marie, primary, Moreau, Anne, primary, Sujobert, Pierre, primary, Pilichowska, Monika, primary, Evens, Andrew M., primary, Chadburn, Amy, primary, Au-Yeung, Rex K.H., primary, Srivastava, Gopesh, primary, Choi, William W. L., primary, Goodlad, John R., primary, Aurer, Igor, primary, Basic-Kinda, Sandra, primary, Gascoyne, Randy D., primary, Davis, Nicholas S., primary, Li, Guojie, primary, Zhang, Jenny, primary, Rajagopalan, Deepthi, primary, Reddy, Anupama, primary, Love, Cassandra, primary, Levy, Shawn, primary, Zhuang, Yuan, primary, Datta, Jyotishka, primary, Dunson, David B., primary, and Davé, Sandeep S., primary

Published
2023
Full Text
View/download PDF

129. Supplementary Methods, Figures S1 - S9 from The Genetic Basis of Hepatosplenic T-cell Lymphoma

Author

McKinney, Matthew, primary, Moffitt, Andrea B., primary, Gaulard, Philippe, primary, Travert, Marion, primary, De Leval, Laurence, primary, Nicolae, Alina, primary, Raffeld, Mark, primary, Jaffe, Elaine S., primary, Pittaluga, Stefania, primary, Xi, Liqiang, primary, Heavican, Tayla, primary, Iqbal, Javeed, primary, Belhadj, Karim, primary, Delfau-Larue, Marie Helene, primary, Fataccioli, Virginie, primary, Czader, Magdalena B., primary, Lossos, Izidore S., primary, Chapman-Fredricks, Jennifer R., primary, Richards, Kristy L., primary, Fedoriw, Yuri, primary, Ondrejka, Sarah L., primary, Hsi, Eric D., primary, Low, Lawrence, primary, Weisenburger, Dennis, primary, Chan, Wing C., primary, Mehta-Shah, Neha, primary, Horwitz, Steven, primary, Bernal-Mizrachi, Leon, primary, Flowers, Christopher R., primary, Beaven, Anne W., primary, Parihar, Mayur, primary, Baseggio, Lucile, primary, Parrens, Marie, primary, Moreau, Anne, primary, Sujobert, Pierre, primary, Pilichowska, Monika, primary, Evens, Andrew M., primary, Chadburn, Amy, primary, Au-Yeung, Rex K.H., primary, Srivastava, Gopesh, primary, Choi, William W. L., primary, Goodlad, John R., primary, Aurer, Igor, primary, Basic-Kinda, Sandra, primary, Gascoyne, Randy D., primary, Davis, Nicholas S., primary, Li, Guojie, primary, Zhang, Jenny, primary, Rajagopalan, Deepthi, primary, Reddy, Anupama, primary, Love, Cassandra, primary, Levy, Shawn, primary, Zhuang, Yuan, primary, Datta, Jyotishka, primary, Dunson, David B., primary, and Davé, Sandeep S., primary

Published
2023
Full Text
View/download PDF

130. Supplemental Figure 3 from Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma

Author

Giulino-Roth, Lisa, primary, van Besien, Herman J., primary, Dalton, Tanner, primary, Totonchy, Jennifer E., primary, Rodina, Anna, primary, Taldone, Tony, primary, Bolaender, Alexander, primary, Erdjument-Bromage, Hediye, primary, Sadek, Jouliana, primary, Chadburn, Amy, primary, Barth, Matthew J., primary, Dela Cruz, Filemon S., primary, Rainey, Allison, primary, Kung, Andrew L., primary, Chiosis, Gabriela, primary, and Cesarman, Ethel, primary

Published
2023
Full Text
View/download PDF

131. Supplemental Figure Legends from Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma

Author

Giulino-Roth, Lisa, primary, van Besien, Herman J., primary, Dalton, Tanner, primary, Totonchy, Jennifer E., primary, Rodina, Anna, primary, Taldone, Tony, primary, Bolaender, Alexander, primary, Erdjument-Bromage, Hediye, primary, Sadek, Jouliana, primary, Chadburn, Amy, primary, Barth, Matthew J., primary, Dela Cruz, Filemon S., primary, Rainey, Allison, primary, Kung, Andrew L., primary, Chiosis, Gabriela, primary, and Cesarman, Ethel, primary

Published
2023
Full Text
View/download PDF

132. Supplemental Figure 5 from Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma

Author

Giulino-Roth, Lisa, primary, van Besien, Herman J., primary, Dalton, Tanner, primary, Totonchy, Jennifer E., primary, Rodina, Anna, primary, Taldone, Tony, primary, Bolaender, Alexander, primary, Erdjument-Bromage, Hediye, primary, Sadek, Jouliana, primary, Chadburn, Amy, primary, Barth, Matthew J., primary, Dela Cruz, Filemon S., primary, Rainey, Allison, primary, Kung, Andrew L., primary, Chiosis, Gabriela, primary, and Cesarman, Ethel, primary

Published
2023
Full Text
View/download PDF

133. Figures S7 - S9 from Mechanism-Based Epigenetic Chemosensitization Therapy of Diffuse Large B-Cell Lymphoma

Author

Clozel, Thomas, primary, Yang, ShaoNing, primary, Elstrom, Rebecca L., primary, Tam, Wayne, primary, Martin, Peter, primary, Kormaksson, Matthias, primary, Banerjee, Samprit, primary, Vasanthakumar, Aparna, primary, Culjkovic, Biljana, primary, Scott, David W., primary, Wyman, Sarah, primary, Leser, Micheal, primary, Shaknovich, Rita, primary, Chadburn, Amy, primary, Tabbo, Fabrizio, primary, Godley, Lucy A., primary, Gascoyne, Randy D., primary, Borden, Katherine L., primary, Inghirami, Giorgio, primary, Leonard, John P., primary, Melnick, Ari, primary, and Cerchietti, Leandro, primary

Published
2023
Full Text
View/download PDF

134. Figure S5 from Mechanism-Based Epigenetic Chemosensitization Therapy of Diffuse Large B-Cell Lymphoma

Author

Clozel, Thomas, primary, Yang, ShaoNing, primary, Elstrom, Rebecca L., primary, Tam, Wayne, primary, Martin, Peter, primary, Kormaksson, Matthias, primary, Banerjee, Samprit, primary, Vasanthakumar, Aparna, primary, Culjkovic, Biljana, primary, Scott, David W., primary, Wyman, Sarah, primary, Leser, Micheal, primary, Shaknovich, Rita, primary, Chadburn, Amy, primary, Tabbo, Fabrizio, primary, Godley, Lucy A., primary, Gascoyne, Randy D., primary, Borden, Katherine L., primary, Inghirami, Giorgio, primary, Leonard, John P., primary, Melnick, Ari, primary, and Cerchietti, Leandro, primary

Published
2023
Full Text
View/download PDF

135. Supplemental Table 1 from Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma

Author

Giulino-Roth, Lisa, primary, van Besien, Herman J., primary, Dalton, Tanner, primary, Totonchy, Jennifer E., primary, Rodina, Anna, primary, Taldone, Tony, primary, Bolaender, Alexander, primary, Erdjument-Bromage, Hediye, primary, Sadek, Jouliana, primary, Chadburn, Amy, primary, Barth, Matthew J., primary, Dela Cruz, Filemon S., primary, Rainey, Allison, primary, Kung, Andrew L., primary, Chiosis, Gabriela, primary, and Cesarman, Ethel, primary

Published
2023
Full Text
View/download PDF

136. Supplemental Figure 1 from Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma

Author

Giulino-Roth, Lisa, primary, van Besien, Herman J., primary, Dalton, Tanner, primary, Totonchy, Jennifer E., primary, Rodina, Anna, primary, Taldone, Tony, primary, Bolaender, Alexander, primary, Erdjument-Bromage, Hediye, primary, Sadek, Jouliana, primary, Chadburn, Amy, primary, Barth, Matthew J., primary, Dela Cruz, Filemon S., primary, Rainey, Allison, primary, Kung, Andrew L., primary, Chiosis, Gabriela, primary, and Cesarman, Ethel, primary

Published
2023
Full Text
View/download PDF

137. Supplemental Table 2 from Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma

Author

Giulino-Roth, Lisa, primary, van Besien, Herman J., primary, Dalton, Tanner, primary, Totonchy, Jennifer E., primary, Rodina, Anna, primary, Taldone, Tony, primary, Bolaender, Alexander, primary, Erdjument-Bromage, Hediye, primary, Sadek, Jouliana, primary, Chadburn, Amy, primary, Barth, Matthew J., primary, Dela Cruz, Filemon S., primary, Rainey, Allison, primary, Kung, Andrew L., primary, Chiosis, Gabriela, primary, and Cesarman, Ethel, primary

Published
2023
Full Text
View/download PDF

138. Table S2 from Mechanism-Based Epigenetic Chemosensitization Therapy of Diffuse Large B-Cell Lymphoma

Author

Clozel, Thomas, primary, Yang, ShaoNing, primary, Elstrom, Rebecca L., primary, Tam, Wayne, primary, Martin, Peter, primary, Kormaksson, Matthias, primary, Banerjee, Samprit, primary, Vasanthakumar, Aparna, primary, Culjkovic, Biljana, primary, Scott, David W., primary, Wyman, Sarah, primary, Leser, Micheal, primary, Shaknovich, Rita, primary, Chadburn, Amy, primary, Tabbo, Fabrizio, primary, Godley, Lucy A., primary, Gascoyne, Randy D., primary, Borden, Katherine L., primary, Inghirami, Giorgio, primary, Leonard, John P., primary, Melnick, Ari, primary, and Cerchietti, Leandro, primary

Published
2023
Full Text
View/download PDF

139. Supplemental Figure 6 from Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma

Author

Giulino-Roth, Lisa, primary, van Besien, Herman J., primary, Dalton, Tanner, primary, Totonchy, Jennifer E., primary, Rodina, Anna, primary, Taldone, Tony, primary, Bolaender, Alexander, primary, Erdjument-Bromage, Hediye, primary, Sadek, Jouliana, primary, Chadburn, Amy, primary, Barth, Matthew J., primary, Dela Cruz, Filemon S., primary, Rainey, Allison, primary, Kung, Andrew L., primary, Chiosis, Gabriela, primary, and Cesarman, Ethel, primary

Published
2023
Full Text
View/download PDF

140. Supplemental Figure 4 from Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma

Author

Giulino-Roth, Lisa, primary, van Besien, Herman J., primary, Dalton, Tanner, primary, Totonchy, Jennifer E., primary, Rodina, Anna, primary, Taldone, Tony, primary, Bolaender, Alexander, primary, Erdjument-Bromage, Hediye, primary, Sadek, Jouliana, primary, Chadburn, Amy, primary, Barth, Matthew J., primary, Dela Cruz, Filemon S., primary, Rainey, Allison, primary, Kung, Andrew L., primary, Chiosis, Gabriela, primary, and Cesarman, Ethel, primary

Published
2023
Full Text
View/download PDF

141. Data from Mechanism-Based Epigenetic Chemosensitization Therapy of Diffuse Large B-Cell Lymphoma

Author

Clozel, Thomas, primary, Yang, ShaoNing, primary, Elstrom, Rebecca L., primary, Tam, Wayne, primary, Martin, Peter, primary, Kormaksson, Matthias, primary, Banerjee, Samprit, primary, Vasanthakumar, Aparna, primary, Culjkovic, Biljana, primary, Scott, David W., primary, Wyman, Sarah, primary, Leser, Micheal, primary, Shaknovich, Rita, primary, Chadburn, Amy, primary, Tabbo, Fabrizio, primary, Godley, Lucy A., primary, Gascoyne, Randy D., primary, Borden, Katherine L., primary, Inghirami, Giorgio, primary, Leonard, John P., primary, Melnick, Ari, primary, and Cerchietti, Leandro, primary

Published
2023
Full Text
View/download PDF

142. Supplemental Figure 2 from Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma

Author

Giulino-Roth, Lisa, primary, van Besien, Herman J., primary, Dalton, Tanner, primary, Totonchy, Jennifer E., primary, Rodina, Anna, primary, Taldone, Tony, primary, Bolaender, Alexander, primary, Erdjument-Bromage, Hediye, primary, Sadek, Jouliana, primary, Chadburn, Amy, primary, Barth, Matthew J., primary, Dela Cruz, Filemon S., primary, Rainey, Allison, primary, Kung, Andrew L., primary, Chiosis, Gabriela, primary, and Cesarman, Ethel, primary

Published
2023
Full Text
View/download PDF

143. Supplementary Methods from Mechanism-Based Epigenetic Chemosensitization Therapy of Diffuse Large B-Cell Lymphoma

Author

Clozel, Thomas, primary, Yang, ShaoNing, primary, Elstrom, Rebecca L., primary, Tam, Wayne, primary, Martin, Peter, primary, Kormaksson, Matthias, primary, Banerjee, Samprit, primary, Vasanthakumar, Aparna, primary, Culjkovic, Biljana, primary, Scott, David W., primary, Wyman, Sarah, primary, Leser, Micheal, primary, Shaknovich, Rita, primary, Chadburn, Amy, primary, Tabbo, Fabrizio, primary, Godley, Lucy A., primary, Gascoyne, Randy D., primary, Borden, Katherine L., primary, Inghirami, Giorgio, primary, Leonard, John P., primary, Melnick, Ari, primary, and Cerchietti, Leandro, primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results